This Plain Language Summary of Publication article (PLSP) from Future Oncology describes a publication reporting on two clinical trials that evaluated larotrectinib, a targeted cancer medication, in 20 patients with TRK fusion-positive lung cancer that had metastasized beyond the lungs. The studies specifically focused on patients whose lung cancer contained a particular genetic alteration in the NTRK gene. The research aimed to determine larotrectinib’s effectiveness in tumor reduction and to document any side effects experienced by participants.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers’ and was published in JCO Precision Oncology.

Visit ASCO Publications using the link to read the original article.